Contact Us

Antitope Ltd
Babraham Research Campus
Babraham
Cambridge CB22 3AT
United Kingdom

Telephone: +44(0) 1223 496190
Fax: +44(0) 1223 496191
Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

PolyTherics Ltd
The London Bioscience Innovation Centre
2 Royal College Street
London NW1 0NH
United Kingdom

Telephone: +44 (0)20 7691 4927
Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

2008

 
08.12.2008
Meet Antitope at Antibody Engineering 2008 (San Diego, Ca, USA 9th December).
Dr. Frank Carr, Director for Biologics Research of Antitope, will be giving a presentation entitled "Therapeutic Antibodies Without Helper T Cell Epitopes" at this year's Antibody Engineering and Antibody Therapeutics conference in San Diego. The presentation will discuss the concept of...
20.11.2008
Antitope to Present at the Oxford Global Proteins Congress 2008, Berlin, Germany, 20th November 2008
Dr. Frank Carr, Director for Biologics Research of Antitope, will give a presentation on "Selection and Design of Therapeutic Antibodies with Reduced Immunogenicity " at the Proteins Congress 2008, Berlin, Germany, 20th November 2008. Dr Carr's presentation will discuss the risk factors...
12.11.2008
Meet Antitope at BIO-Europe 2008 (Mannheim 17-19 November 2008)
Antitope will be participating in the Business Partnering Forum at the BIO-Europe and welcome the opportunity to discuss potential collaborations with companies that are interested in assessing and/or removing immunogenicity from protein therapeutics. Meetings can be arranged through the Conference...
12.11.2008
Antitope Ltd. UK Announces EpiScreen Collaboration With Isu Abxis Co., Ltd.
Cambridge, UK - 12 November 2008 - Antitope Ltd. ("Antitope") today announced a research collaboration with the Korean biopharmaceutical company Isu Abxis Co., Ltd ("Isu Abxis") in which Antitope will apply its proprietary EpiScreenTM technology to profile the immunogenicity of...
27.10.2008
Antitope Ltd. Announces Antibody Research Agreement With Boehringer Ingelheim
Cambridge UK, 27 October 2008 - Antitope Ltd. ("Antitope") today announced a research agreement with Boehringer Ingelheim ("Boehringer Ingelheim") for the modification of monoclonal antibodies. Under the Agreement, Antitope will apply its proprietary Composite Human AntibodyTM...
07.10.2008
Meet Antitope at BioJapan 2008, Pacifico Yokohama, Japan 15th-17th October
Antitope will be participating in the Business Partnering Forum at the BioJapan meeting in Yokohama and welcome the opportunity to discuss potential collaborations with companies that are interested in assessing and/or removing immunogenicity from protein therapeutics. Meetings can be arranged...
24.09.2008
Antitope Ltd, UK. Announces EpiScreen Collaboration with Hanmi Pharmaceutical Company Ltd, Korea.
24th September 2008 - Antitope Ltd. today announced a research collaboration with leading Korean company Hanmi Pharmaceutical Company Limited ("Hanmi") where Antitope will apply EpiScreenTM technology to profile the immunogenicity of therapeutic proteins. "We are delighted to be...
22.09.2008
Antitope to Present at the ELRIG Conference in Bournemouth, UK, 24th September 2008
Dr. Matthew Baker, CSO of Antitope, will give a presentation on ‘Overcoming Adverse Immunogenicity Against Therapeutic Antibodies' at the European Laboratory Robotics Interest Group Conference in Bournemouth UK, 24th September 2008. Dr Baker's presentation will discuss data from clinical...
15.09.2008
Antitope to Present at bioLOGIC Europe 2008 in Geneva on 18th Sept 2008
Dr. Matthew Baker, CEO of Antitope, will chair a conference session entitled "Biological Product Development" at this years biologic 2008 in Geneva. The session will include discussion concerning "Adding Value to Biologics Development", "Dealing with Immunogenicity and...
08.09.2008
Antitope to Present at the Next Generation Protein Therapeutics Summit in Budapest on 11th Sept 2008
Dr. Matthew Baker, CSO of Antitope, will chair a conference session entitled "Measuring and Reducing Immunogenicity" at this year's Next Generation Protein Therapeutics Conference in Budapest. Dr Baker will also be presenting a paper during the session on "Early Pre-clinical...
02.09.2008
Antitope to Present at Protein Therapeutics Discovery and Development, San Diego, 7th September 2008
Dr. Matthew Baker, CSO of Antitope, will speak at a workshop entitled "In Silico and In Vitro Screening for Immunogenicity in Drug Discovery" at the Protein Therapeutics - Discovery and Development Conference in San Diego, CA, 7th September 2008. Dr Baker's presentation, "Selection...
28.08.2008
Antitope to Present at Asia Antibody Congress 2008, 4th September 2008, Singapore
Dr. Frank Carr, Director for Biologics Research of Antitope, will be giving a presentation entitled ‘Therapeutic Antibodies Without Helper T Cell Epitopes" at this year's Asia Antibody Congress conference in Singapore. The presentation will discuss the concept of therapeutic antibodies...
04.08.2008
Antitope to Present at DDT, Boston, USA; August 7 2008
Dr. Matthew Baker, CSO of Antitope, will be presenting a workshop entitled ‘Immunogenicity Prediction for New Biologis' at this year's Drug Discovery and Development of Innovative Therapeutics Conference in Boston. The workshop will discuss, the critical question: How can the potential risk...
23.07.2008
ImmunoCellular Therapeutics Signs with Antitope for Humanization of Antibody Product Candidates
LOS ANGELES, CA - July 23, 2008 - ImmunoCellular Therapeutics, Ltd. (OTC: IMUC.OB) (IMUC), a biotechnology company, announced today that it has signed a research agreement with Antitope Ltd. for the humanization of IMUC's monoclonal antibodies. IMUC is advancing its monoclonal antibodies toward...
10.07.2008
Antitope Ltd. Announces Antibody Research Agreement with Fusion Antibodies Ltd. (Belfast, UK)
Cambridge UK, 10th July 2008 - Antitope Ltd. ("Antitope") today announced a research agreement with Fusion Antibodies Limited ("Fusion") for the generation of therapeutic monoclonal antibodies. The research program will use Antitope's proprietary Composite Human AntibodyTM...
25.06.2008
Antitope to Present at 2008 AAPS National Biotechnology Conference, Toronto, Canada; June 26 2008
Dr. Matthew Baker, CSO of Antitope, will be presenting a paper entitled ‘Immunological Background' in the session ‘Unwanted Immunogenicity of Protein Therapeutics' at this year's AAPS National Biotechnology Conference in Toronto. Dr. Baker will be presenting in a session covering many...
07.06.2008
Antitope to Present at "Cell Line Development and Engineering" San Diego, June 24 2008
Antitope scientists will be presenting a paper entitled "Immunogenicity of Antibodies".  
07.06.2008
Antitope to Present at "Recombinant Antibodies" Dublin, June 26 2008
Dr Frank Carr, Director for Biologics Research, will be presenting a paper entitled "Overcoming Adverse Immunogenicity Against Therapeutics Antibodies ". 
07.06.2008
Antitope to Present at "Annual World Cancer Congress 2008" Shanghai, June 13 2008
Dr Frank Carr, Director for Biologics Research, will be presenting a paper entitled "Therapeutic Antibodies with Helper T Cell Epitopes". 
28.05.2008
Meet Antitope at BIO International Convention 2008 (San Diego, CA, USA 17th - 20th June)
Antitope will be participating in the Business Partnering Forum at the BIO International Convention and welcome the opportunity to discuss potential collaborations with companies that are interested in assessing and/or removing immunogenicity from protein therapeutics. Meetings can be arranged...
29.02.2008
Antitope and Keel Pharmaceuticals (Boston, MA) announce successful Composite Human Antibody project
28 February 2008 Antitope Ltd (Cambridge, UK), a leader in the generation of therapeutic humanized antibodies, and Keel Pharmaceuticals, Inc. (Cambridge, MA), an emerging leader in the development of therapeutics for the treatment of autoimmune disease, today announced the successful completion of...
20.02.2008
Antitope to Present at "2nd Annual Conference on Recombinant Antibodies" Berlin, Feb 27 2008
Antitope to Present at "2nd Annual Conference on Recombinant Antibodies" Melia Hotel, Berlin, Feb 27th 2008 Dr Matthew Baker, Chief Scientific Officer, will be presenting a paper entitled "Assessment of T-cell Epitopes as a Key Risk Factor in the Development of Anti-Therapeutic...
07.02.2008
Antitope to Present at "Antibody Engineering Asia " Mandarin Meritus, Singapore, Feb 26th 2008
Dr Frank Carr, Director of Biologics Research will be presenting a paper entitled "Overcoming Adverse Immunogenicity Against Therapeutic Antibodies". This paper will discuss the process of engineering antibodies without T cell epitopes to minimize the risk of immunogenicity in the clinic...
23.01.2008
Antitope Ltd, Announces Research Agreement with China Synthetic Rubber Corporation, Taipei, Taiwan
23rd January 2008 - Antitope Ltd., a privately-held antibody and protein engineering company, today announced a research agreement with the China Synthetic Rubber Corporation (CSRC). Under the Agreement, Antitope will apply Composite Human AntibodyTM technology to produce two fully humanized...